Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BMED
iShares Health Innovation Active ETF
$26.12
+0.5%
$25.19
$20.57
$27.02
$4.18M0.771,813 shs458 shs
CLIA
Veridien Climate Action ETF
$18.61
-0.2%
$18.61
$16.48
$21.28
$23.45M1.349,925 shs75,500 shs
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
$32.41
+0.7%
$31.33
$24.76
$32.56
$3.89M0.641,498 shs204 shs
THNR
Amplify Weight Loss Drug & Treatment ETF
$22.92
+0.7%
$22.83
$18.56
$28.19
$2.98MN/A2,052 shs2,422 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BMED
iShares Health Innovation Active ETF
+0.46%-0.72%+3.28%+8.43%-0.38%
CLIA
Veridien Climate Action ETF
0.00%0.00%0.00%0.00%0.00%
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
+0.68%-0.31%+4.51%+8.36%+25.57%
THNR
Amplify Weight Loss Drug & Treatment ETF
+0.70%-0.99%0.00%+3.43%-17.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/AN/AN/AN/A
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
N/AN/AN/AN/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BMED
iShares Health Innovation Active ETF
2.76
Moderate Buy$26.12N/A
CLIA
Veridien Climate Action ETF
2.50
Hold$18.61N/A
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
0.00
N/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
2.57
Moderate Buy$22.92N/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/AN/A
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
N/AN/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BMED
iShares Health Innovation Active ETF
N/AN/A24.91N/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/A16.68N/AN/AN/AN/AN/A
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
N/AN/A16.82N/AN/AN/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/A24.31N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BMED
iShares Health Innovation Active ETF
N/AN/AN/AN/AN/A
CLIA
Veridien Climate Action ETF
N/AN/AN/AN/AN/A
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
$0.983.02%N/AN/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
$0.220.96%N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BMED
iShares Health Innovation Active ETF
N/A160,000N/ANot Optionable
CLIA
Veridien Climate Action ETF
N/A1.26 millionN/ANot Optionable
KBUF
KraneShares 90% KWEB Defined Outcome Through January 2026 ETF
N/A120,000N/AN/A
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A130,000N/AN/A

Media Sentiment Over Time

iShares Health Innovation Active ETF NYSEARCA:BMED

$26.12 +0.12 (+0.46%)
As of 08/29/2025 04:10 PM Eastern

The BlackRock Future Health ETF (BMED) is an exchange-traded fund that is based on the MSCI All Country World index. The fund is actively managed to invest in global equities in the health sciences industry. BMED was launched on Sep 29, 2020 and is managed by BlackRock.

Veridien Climate Action ETF NYSEARCA:CLIA

$18.61 -0.04 (-0.21%)
As of 08/16/2024

The Veridien Climate Action ETF (CLIA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed, non-transparent ETF that seeks to invest in companies, via US-listed stocks or ADRs from around the world, that are considered to be making a substantial contribution to mitigating climate change. The fund utilizes the Precidian non-transparent model CLIA was launched on May 8, 2023 and is managed by Veridien.

KraneShares 90% KWEB Defined Outcome Through January 2026 ETF NYSEARCA:KBUF

$32.41 +0.22 (+0.68%)
As of 08/29/2025 04:10 PM Eastern

The KraneShares 90% KWEB Defined Outcome January 2026 ETF (KBUF) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund seeks to track the total return of the KraneShares CSI China Internet ETF (KWEB) up to a cap, with a 90% downside hedge over a two-year outcome period. The actively managed fund holds shares of the underlying ETF and options to obtain exposure. KBUF was launched on Feb 8, 2024 and is issued by KraneShares.

Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR

$22.92 +0.16 (+0.70%)
As of 08/29/2025 04:10 PM Eastern

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.